Presence or absence of a gallate moiety on catechins affects their cellular transport

The Journal of Pharmacy and Pharmacology
Masaaki KadowakiKoji Furuno

Abstract

The accumulation of (-)-epicatechin (EC), a non-gallate catechin, was significantly lower than that of (-)-epicatechin gallate (ECG), a gallate catechin, in Caco-2 cells. Using Caco-2 cell monolayers cultured in transwells, the transport of catechins in the basolateral-to-apical direction was much higher than that in the apical-to-basolateral direction, suggesting the involvement of an efflux transporter. Moreover, the results suggest that involvement of a transporter in EC efflux is greater than that for ECG. Treatment with transporter inhibitors MK571, quinidine or mitoxantrone, which inhibit MRP2, P-glycoprotein (P-gp) and BCRP, respectively, led to an increase in the accumulation of EC into Caco-2 cells and a decrease in the Papp ratio (Papp B-->A/Papp A-->B) for EC. These transporters seemed to be involved in EC efflux. BCRP was not an efflux transporter for ECG, and the influences of MRP2 and P-gp on ECG efflux were lower than for EC. Thus, efflux transporters appear to be responsible for the difference in cellular accumulation of EC versus ECG, suggesting that the presence or absence of a gallate moiety in the catechin structure influences the transporters.

References

Aug 1, 1997·The European Respiratory Journal·E Lechapt-ZalcmanJ F Bernaudin
Jan 1, 1997·Journal of Cellular Biochemistry. Supplement·S K Katiyar, H Mukhtar
Oct 18, 2000·Biochemical and Biophysical Research Communications·G KuhnleU Hahn
Jun 1, 2001·The Journal of Nutrition·J L DonovanC Rémésy
Jun 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·S J DuffyJ F Keaney
Feb 21, 2002·Biochimica Et Biophysica Acta·Julie JodoinRichard Beliveau
Apr 4, 2002·The Australian and New Zealand Journal of Psychiatry·Jennifer Radden
Jul 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jaya Bharathi Vaidyanathan, Thomas Walle
Oct 3, 2002·Annual Review of Pharmacology and Toxicology·Matthias SchwabMartin F Fromm
Apr 5, 2003·Toxicology Letters·Adrienn BodóBalázs Sarkadi
Jun 6, 2003·Bioscience, Biotechnology, and Biochemistry·Yutaka Konishi, Makoto Shimizu
Sep 13, 2003·The Journal of Pharmacology and Experimental Therapeutics·Jaya Bharathi Vaidyanathan, Thomas Walle
Apr 23, 2004·Molecular Pharmacology·Shuzhong ZhangMarilyn E Morris
Aug 3, 2004·The Journal of Pharmacy and Pharmacology·Shuji KitagawaShizu Kamiyama
Oct 7, 2004·European Journal of Pharmacology·Marcel W L Koo, Chi H Cho
Oct 16, 2004·The Journal of Pharmacy and Pharmacology·Yuying MeiJianwen Liu
Nov 16, 2004·International Journal of Pharmaceutics·Li ZhangZhong Zuo
Sep 6, 2005·Biochemical Pharmacology·Shuji KitagawaYasumasa Ikeshiro
Oct 8, 2005·Pharmacology & Therapeutics·Mikihisa TakanoTeruo Murakami

❮ Previous
Next ❯

Citations

Oct 25, 2016·The Journal of Nutritional Biochemistry·Olga KrupkovaKarin Wuertz-Kozak
Jul 6, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Admire DubeIan Larson
Aug 1, 2014·Bioscience, Biotechnology, and Biochemistry·Takayuki YamamotoTeruo Kawada
Oct 22, 2016·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Keiko UnnoYoriyuki Nakamura
Feb 22, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Meng ShiXin-Qiang Zheng
Jun 20, 2019·Nutrients·Dylan O'Neill Rothenberg, Lingyun Zhang
Feb 22, 2018·PloS One·Catharina SchollJulia Carolin Stingl
Apr 16, 2019·Journal of Agricultural and Food Chemistry·Yafang WangDaxiang Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.